AIM: To study the efficacy and safety of entecavir (ETV) as first-line therapy for hepatitis B virus (HBV) reactivation due to immunosuppression. METHODS: Four patients that were treated with different immunosuppressive regimens for hematological malignancies, who presented with HBV reactivation were treated with ETV. Clinical outcome, biochemical and virological factors, including quantitative hepatitis B surface antigen (HBsAg) were studied. RESULTS: In all patients, ETV induced suppression of HBV, and rapid clinical improvement without side effects. In one patient with an alanine aminotransferase (ALT) flare, tenofovir was added after 3 mo of treatment. Until death from disease progression at 6 mo after treatment initiation, this patient did not clear HBV infection. Retrospectively, it is highly probable that the patient had been non-adherent. In the other three patients, the virological responses were associated with an expeditious decrease in quantitative HBsAg titers with negativity after 2 mo, and all three had HBsAg seroconversion. In one patient, HBV DNA reached a plateau after 3 mo, before becoming undetectable after 1 year, despite early ALT normalization and undetectable quantitative HBsAg. CONCLUSION: ETV seems to be effective and safe treatment for HBV reactivation. Monitoring of quantitative HBsAg might be an additional useful tool to monitor treatment response.
AIM: To study the efficacy and safety of entecavir (ETV) as first-line therapy for hepatitis B virus (HBV) reactivation due to immunosuppression. METHODS: Four patients that were treated with different immunosuppressive regimens for hematological malignancies, who presented with HBV reactivation were treated with ETV. Clinical outcome, biochemical and virological factors, including quantitative hepatitis B surface antigen (HBsAg) were studied. RESULTS: In all patients, ETV induced suppression of HBV, and rapid clinical improvement without side effects. In one patient with an alanine aminotransferase (ALT) flare, tenofovir was added after 3 mo of treatment. Until death from disease progression at 6 mo after treatment initiation, this patient did not clear HBV infection. Retrospectively, it is highly probable that the patient had been non-adherent. In the other three patients, the virological responses were associated with an expeditious decrease in quantitative HBsAg titers with negativity after 2 mo, and all three had HBsAg seroconversion. In one patient, HBV DNA reached a plateau after 3 mo, before becoming undetectable after 1 year, despite early ALT normalization and undetectable quantitative HBsAg. CONCLUSION:ETV seems to be effective and safe treatment for HBV reactivation. Monitoring of quantitative HBsAg might be an additional useful tool to monitor treatment response.
Authors: M A Stange; O Tutarel; S Pischke; A Schneider; C P Strassburg; T Becker; H Barg-Hock; M Bastürk; K Wursthorn; M Cornberg; M Ott; T F Greten; M P Manns; H Wedemeyer Journal: Z Gastroenterol Date: 2010-02-02 Impact factor: 2.000
Authors: H L Tillmann; J Hadem; L Leifeld; K Zachou; A Canbay; C Eisenbach; I Graziadei; J Encke; H Schmidt; W Vogel; A Schneider; U Spengler; G Gerken; G N Dalekos; H Wedemeyer; M P Manns Journal: J Viral Hepat Date: 2006-04 Impact factor: 3.728
Authors: Ching-Lung Lai; Daniel Shouval; Anna S Lok; Ting-Tsung Chang; Hugo Cheinquer; Zachary Goodman; Deborah DeHertogh; Richard Wilber; Richard C Zink; Anne Cross; Richard Colonno; Lori Fernandes Journal: N Engl J Med Date: 2006-03-09 Impact factor: 91.245
Authors: Jessica P Hwang; John M Vierling; Andrew D Zelenetz; Susan C Lackey; Rohit Loomba Journal: Support Care Cancer Date: 2012-08-30 Impact factor: 3.603
Authors: Massimo Marignani; Elia Gigante; Paola Begini; Alfredo Marzano; Michela di Fonzo; Ilaria Deli; Sara Gallina; Maria Christina Cox; Gianfranco Delle Fave Journal: World J Gastrointest Oncol Date: 2012-03-15
Authors: Manzoor A Wani; Jaswinder S Sodhi; Ghulam N Yatoo; Altaf Shah; Sajad Geelani; Showkat A Zargar; Ghulam M Gulzar; Mushtaq Khan; Sheikh A Aziz Journal: J Clin Exp Hepatol Date: 2020-07-08
Authors: Oguz Durmus; Levent Tekin; Alparslan Bayram Carli; Engin Cakar; Ali Acar; Asim Ulcay; Umit Dincer; Mehmet Zeki Kiralp Journal: Rheumatol Int Date: 2011-11-16 Impact factor: 3.580